Request Demo
Last update 06 Mar 2025
F-182112
Last update 06 Mar 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms F 182112, F-182112 |
Target |
Action- |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with F-182112NCT04984434
A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.
100 Clinical Results associated with F-182112
Login to view more data
100 Translational Medicine associated with F-182112
Login to view more data
100 Patents (Medical) associated with F-182112
Login to view more data
1
Literatures (Medical) associated with F-182112Journal of hematology & oncology
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Letter
Author: Song, Yongping ; Ren, Quan ; Zhao, Juanjuan ; Liu, Xinyuan ; Guo, Xiangqian
Abstract:
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.
100 Deals associated with F-182112
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory Multiple Myeloma | Phase 1 | China | 30 Jul 2021 | |
| Relapse multiple myeloma | Phase 1 | China | 30 Jul 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 22 | fnpdoscgjw(xcdkscqniw) = myzjlyubjt njsxnblixq (enjaoaxfeb ) View more | - | 09 Dec 2023 | |||
Phase 1 | 16 | fymmrglfbg(qqejrrrwoq) = maxlnfjvle idzdroybwh (kytzjrqwzw ) View more | Positive | 26 May 2023 | |||
(pts treated with ≥ 10 μg/kg F182112) | kpekagczuk(iygzmqvzie) = gkvaprulmm eysbeflpok (rqoltjflqp ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free